Form 4: BioMarin CTO Sells 16,486 Shares Under 10b5-1 Plan

BioMarin Pharmaceutical Inc.'s EVP, Chief Technical Officer, Charles Greg Guyer, sold 16,486 shares of common stock for approximately $60.46 per share.

Summary

• Charles Greg Guyer, EVP, Chief Technical Officer of BioMarin Pharmaceutical Inc. (BMRN), sold 16,486 shares of common stock.
• The transaction occurred on March 11, 2026.
• The shares were sold at a weighted average price of $60.46, with individual sale prices ranging from $60.39 to $60.62.
• Following the sale, Guyer beneficially owns 79,953 shares of BioMarin common stock.
• The transaction was made pursuant to a Rule 10b5-1 trading plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, typical for executive financial planning, especially given the execution under a Rule 10b5-1 plan and the reporting person's continued significant ownership.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider sales, especially those executed under a Rule 10b5-1 plan, are common for executives managing personal finances and diversifying portfolios. This transaction by BioMarin's CTO is a routine disclosure and does not necessarily indicate a change in the company's fundamental outlook or the executive's confidence, particularly given the remaining significant holding.

Stakeholder Impact

• Shareholders: The sale represents a reduction in insider ownership, though it was pre-planned and the executive retains a substantial holding.

Key Dates

Recommendation

The insider sale by the EVP, Chief Technical Officer, Charles Greg Guyer, is a routine transaction executed under a pre-arranged Rule 10b5-1 trading plan. This type of sale is typically for personal financial management and diversification, rather than a reflection of a change in the company's fundamental outlook. Guyer retains a significant beneficial ownership of 79,953 shares, indicating continued alignment with shareholder interests. Therefore, the filing itself does not provide new information warranting a change in investment thesis, leading to a 'hold' recommendation.

Keywords

BioMarin Pharmaceutical, BMRN, Insider Trading, Form 4, Stock Sale, Executive Compensation, Charles Greg Guyer, Chief Technical Officer, 10b5-1 Plan